26 July 2012 – results/fund raising

The group’s results to 30 April are largely irrelevant in terms of figures given the early stage of its development, but it is now focusing the business on its medical diagnostic companies, Parsortix (cancer) and Novocellus (IVF treatment).  These have seen good progress over the last year and to help fund future developments the group has issued just over 1.64m shares at 40p in a share placing.  The share price has fallen back of late due to the lack of news from the company but we continue to rate the shares a SPECULATIVE BUY.